Better evidence for a better world

Campbell evidence and gap maps

Coming soon – Campbell EGMs are a new evidence synthesis product. Plain language summaries of our EGMs will be published on this website. The interactive EGMs and full EGM reports will be available in our journal on the Wiley Online Library platform: click here.



Learn more about Campbell EGMs

Other EGMs

Campbell has produced maps on other topics, sometimes in partnership with other organisations.



See our other EGMs
Cognitive-behavioural treatment for amphetamine-type stimulants (ATS)-use disorders

Additional Info

  • Authors: Takayuki Harada, Hiroshi Tsutomi, Rintaro Mori, David Wilson
  • Published date: 2019-07-25
  • Coordinating group(s): Crime and Justice
  • Type of document: Review
  • Title: Cognitive-behavioural treatment for amphetamine-type stimulants (ATS)-use disorders
  • English:

    PLAIN LANGUAGE SUMMARY

    Cognitive‐behavioural treatment for amphetamine‐type stimulants‐use disorders

    What was the aim of this review?

    The aim of this Cochrane review was to find out whether cognitive‐behavioural treatment (CBT) is effective to treat people with amphetamine‐type stimulants (ATS)‐use disorders. Researchers in the Drugs and Alcohol Group of Cochrane collected and analysed all relevant studies to answer this question and found two studies.

    Key messages

    The current evidence was inadequate to draw any firm evidence‐based treatment recommendations for the client population.

    What was studied in the review?

    ATS are a group of synthetic stimulants and their use has been widespread globally. These types of drugs are highly addictive and prolonged use may result in a series of mental and physical symptoms including anxiety, confusion, insomnia (difficulty sleeping), mood disturbances, cognitive impairments (difficulty thinking and understanding), paranoia (irrational feeling that people are 'out to get you'), hallucinations (where someone experiences something that does not exist outside their own mind) and delusion (a mistaken belief).

    Currently there is no widely accepted treatment for ATS‐use disorder. However, CBT is often the first choice of treatment. It is a psychological treatment (talking therapy) approach to modify distorted thoughts and beliefs, and maladaptive behaviours (things that people do to stop them from adjusting to situations). The effectiveness of CBT for other substance‐use disorders (e.g. alcohol‐, opioid‐ and cocaine‐use disorders) has been well documented and as such this basic treatment approach has been applied to the ATS‐use disorder. These types of therapies are expected to prevent relapse and decrease drug use.

    What are the main results of the review?

    The review authors found two eligible studies. Both studies were conducted in Australia. One study compared a single session of brief CBT to a waiting‐list control where participants received no treatment during the study period. One study compared web‐based CBT to a waiting‐list control. Both studies were funded by the Australian Government of Health and Ageing.

    The review showed that when participants received CBT, compared to waiting‐list control, there was no difference. There was insufficient evidence to conclude that CBT was effective or ineffective at treating ATS‐use disorders.

    How up‐to‐date is this review

    The review authors searched for studies that had been published up to July 2018.

  • See the full review: https://onlinelibrary.wiley.com/doi/10.1002/cl2.1026

Select language:

PLAIN LANGUAGE SUMMARY

Cognitive‐behavioural treatment for amphetamine‐type stimulants‐use disorders

What was the aim of this review?

The aim of this Cochrane review was to find out whether cognitive‐behavioural treatment (CBT) is effective to treat people with amphetamine‐type stimulants (ATS)‐use disorders. Researchers in the Drugs and Alcohol Group of Cochrane collected and analysed all relevant studies to answer this question and found two studies.

Key messages

The current evidence was inadequate to draw any firm evidence‐based treatment recommendations for the client population.

What was studied in the review?

ATS are a group of synthetic stimulants and their use has been widespread globally. These types of drugs are highly addictive and prolonged use may result in a series of mental and physical symptoms including anxiety, confusion, insomnia (difficulty sleeping), mood disturbances, cognitive impairments (difficulty thinking and understanding), paranoia (irrational feeling that people are 'out to get you'), hallucinations (where someone experiences something that does not exist outside their own mind) and delusion (a mistaken belief).

Currently there is no widely accepted treatment for ATS‐use disorder. However, CBT is often the first choice of treatment. It is a psychological treatment (talking therapy) approach to modify distorted thoughts and beliefs, and maladaptive behaviours (things that people do to stop them from adjusting to situations). The effectiveness of CBT for other substance‐use disorders (e.g. alcohol‐, opioid‐ and cocaine‐use disorders) has been well documented and as such this basic treatment approach has been applied to the ATS‐use disorder. These types of therapies are expected to prevent relapse and decrease drug use.

What are the main results of the review?

The review authors found two eligible studies. Both studies were conducted in Australia. One study compared a single session of brief CBT to a waiting‐list control where participants received no treatment during the study period. One study compared web‐based CBT to a waiting‐list control. Both studies were funded by the Australian Government of Health and Ageing.

The review showed that when participants received CBT, compared to waiting‐list control, there was no difference. There was insufficient evidence to conclude that CBT was effective or ineffective at treating ATS‐use disorders.

How up‐to‐date is this review

The review authors searched for studies that had been published up to July 2018.

See the full review

Contact us

  • P.O. Box 222, Skøyen,
    N-0213 Oslo, Norway
  • (+47) 21 07 81 00
  • info@campbellcollaboration.org